Acura is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing the Company’s proprietary LIMITX™, IMPEDE® and AVERSION® Technology platforms. Acura’s products and product candidates are based on widely-used commercially available products and do not alter the safety and efficacy of the active pharmaceutical ingredients that are intended to effectively treat the patient while simultaneously discouraging common methods of product tampering and abuse, including:
- Addressing abuse by excess oral consumption or accidental over-ingestion of tablets
- Intravenous injection by forming a viscous gelatinous mixture when tablets and capsules are dissolved in solvents suitable for injection
- Nasal snorting by inducing disliked nasal discomfort when tablets or capsules are crushed and snorted
- Extraction and conversion of the active ingredient into abused drugs such as methamphetamine
Acura’s LIMITX™ Technology is the newest platform currently in development. LIMITX™ Technology is intended to address abuse by excess oral consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets. LIMITX™ may also have utility in deterring snorting of crushed pills and dissolving pills for injection.
Acura’s AVERSION® Technology platform has been successfully utilized in developing multiple abuse deterrent opioid analgesic product candidates. The first product commercialized utilizing AVERSION® Technology is OXAYDO® (oxycodone hydrochloride) Tablets CII. AVERSION® is a combination of gelling ingredients and nasal irritants designed to discourage abuse of pills by snorting and injection.
The Company’s IMPEDE® Technology platform is an advanced polymer matrix that is used in NEXAFED®, Acura’s pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine.
Acura has multiple abuse deterrent products in development utilizing all three of its technologies. The company is primarily focused on the development of LIMITX™ and IMPEDE® products at this time.